Schellekens Kh
Janssen Pharmaceutica
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Schellekens Kh.
Drug Research | 1960
Paul A. J. Janssen; Anton H. M. Jageneau; Schellekens Kh
SummaryHaloperidol (R 1625) is 50 to 100 times more active than chlorpromazine as an inhibitor of exploratory motor behaviour in rats. Emotional defaecation in rats is inhibited by both drugs at similar dose levels.
European Journal of Pharmacology | 1970
Paul A. J. Janssen; C. J. E. Niemegeers; Schellekens Kh; Fred M. Lenaerts; Frans J. Verbruggen; Jan M. Van Nueten; Wolfgang Schaper
Abstract R 16341, 4-(4-chloro- a , a , a -trifluoro-m-tolyl)-1[4,4-bis(p-fluorophenyl)butyl]-4-piperidinol is a new member of the potent and long-acting series of diphenylbutyl piperidine neuroleptics of which pimozide is the prototype. In animals the pharmacological profile of R 16341 resembles that of typical neuroleptic compounds. R 16341 is very potent by the oral route and has a longer duration of action than any other neuroloptic we have tested. At 4 times the minimum ED 50 -value of the anti-apomorphine test in dogs, R 16341 has a duration of action of about 7 days. The onset of action of R 16341 is gradual and smooth and its peak effect is generally reached 24 to 48 hr after administration. R 16341 is relatively atoxic with a safety margin of 1:1000 in rats and dogs. Qualitatively R 16341 is more closely related to haloperidol and pimozide than to chlorpromazine, the side-effect liability is expected to be lower than that of chlorpromazine, when hypotensive and autonomic side-effects are concerned and to be lower than that of haloperidol when undesirable neurological side-effects are concerned.
Cellular and Molecular Life Sciences | 1977
F. Awouters; C. J. E. Niemegeers; J. Van den Berk; J.M. Van Nueten; Fred M. Lenaerts; M. Borgers; Schellekens Kh; A. Broeckaert; J. De Cree; P. A. J. Janssen
Oxatomide is a new potent inhibitor of anaphylactic and allergic reactions. After oral administration, the compound both inhibits the release of endogenous histamine and prevents the effects of exogenous histamine, at comparable doses. The combination of these effects appears to be the basis of the effectiveness of oxatomide in allergic reactions and may lead to clinical applications different from classical antihistaminics and from cromoglycate.
Nature | 1990
Rudi Pauwels; Koen Andries; Jan Desmyter; Dominique Schols; Michael Joseph Kukla; Henry J. Breslin; Alfons Raeymaeckers; Jozef Van Gelder; R. Woestenborghs; J. Heykants; Schellekens Kh; Marcel Janssen; Erik De Clercq; Paul A. J. Janssen
Journal of Pharmacology and Experimental Therapeutics | 1988
P. A. J. Janssen; C. J. E. Niemegeers; F. Awouters; Schellekens Kh; Anton A. H. P. Megens; Theo F. Meert
Drug Research | 1966
Paul A. J. Janssen; Niemegeers Cj; Schellekens Kh
Psychopharmacology | 1960
Paul A. J. Janssen; Anton H. M. Jageneau; Schellekens Kh
Journal of Medicinal Chemistry | 1959
Paul A. J. Janssen; Corn. van De Westeringh; Anton H. M. Jageneau; Paul J. A. Demoen; Bert K. F. Hermans; Georges Henri Paul Van Daele; Schellekens Kh; Cyriel A. M. Van der Eycken; C. J. E. Niemegeers
Drug Research | 1967
Paul A. J. Janssen; Niemegeers Cj; Schellekens Kh; Lenaerts Fm
Drug Research | 1971
Paul A. J. Janssen; Niemegeers Cj; Schellekens Kh; Lenaerts Fm